X7635bae0.a49b.4c58.ae88.de85f60b4ab6
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.280
- OXIDATIVE_PHOSPHORYLATION+0.280
- E2F_TARGETS+0.260
- TGF_BETA_SIGNALING+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.250
- G2M_CHECKPOINT+0.240
- FATTY_ACID_METABOLISM+0.220
- UV_RESPONSE_UP+0.220
- PEROXISOME+0.210
- ADIPOGENESIS+0.200
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ALLOGRAFT_REJECTION-0.470
- INTERFERON_GAMMA_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.360
- IL6_JAK_STAT3_SIGNALING-0.340
- INFLAMMATORY_RESPONSE-0.320
- KRAS_SIGNALING_UP-0.310
- COMPLEMENT-0.300
- APICAL_JUNCTION-0.250
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202419 | — | — | 0.858 |
| 2 | DRR168570 | — | — | 0.856 |
| 3 | 1ac3f1b2-5b83-470c-b1d3-d35d813f3e65 | — | — | 0.838 |
| 4 | R286 | — | — | 0.822 |
| 5 | SRR1516049 | — | — | 0.817 |
| 6 | DRR168591 | — | — | 0.816 |
| 7 | TCGA-A2-A0CT-01A-31R-A056-07 | — | B | 0.816 |
| 8 | SAMN03290953 | — | — | 0.814 |
| 9 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.811 |
| 10 | SAMN03290941 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |